Last reviewed · How we verify
Gleevec
At a glance
| Generic name | Gleevec |
|---|---|
| Also known as | Imatinib Mesylate, STI-571, Imatinib, NSC-716051, imatinib mesylate |
| Sponsor | M.D. Anderson Cancer Center |
| Target | Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Blastic phase chronic myeloid leukemia
- Chronic Myelocytic Leukemia Accelerated Phase
- Chronic eosinophilic leukemia
- Chronic phase chronic myeloid leukemia
- Dermatofibrosarcoma protuberans
- Gastrointestinal stromal tumor
- Idiopathic hypereosinophilic syndrome
- Myelodysplastic/myeloproliferative diseases with re-arrangements of the gene for platelet-derived growth factor receptor (PDGFR)
- Philadelphia Chromosome Positive Chronic Myelocytic Leukemia
- Philadelphia chromosome-positive acute lymphoblastic leukemia
- Systemic mast cell disease
Common side effects
- Edema
- Nausea
- Vomiting
- Muscle cramps
- Musculoskeletal pain
- Diarrhea
- Rash
- Fatigue
- Abdominal pain
- Neutropenia
- Thrombocytopenia
- Cytopenias
Serious adverse events
- Acute liver failure
- Grade 3 or 4 neutropenia
- Grade 3 or 4 thrombocytopenia
- Severe hepatotoxicity
- Pulmonary edema
- Pleural effusion
- Ascites
Key clinical trials
- A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia (PHASE3)
- Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML (PHASE2)
- Trial of Imatinib for Hospitalized Adults With COVID-19 (PHASE3)
- Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor (PHASE1)
- Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase (PHASE2)
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy (PHASE3)
- Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia (PHASE2)
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |